Memorial Sloan-Kettering Cancer Center (MSKCC) is a free-standing NCI-designated Comprehensive Cancer Research Center dedicated to research and training, with the mission of changing and setting the standards of treatment, prevention and control of cancer through inpatient and outpatient care. MSKCC's research programs are grouped into three categories: Basic Research (Regulation of Cell Behavior, Developmental and Stem Cell Biology, Genomic Integrity, and Molecular Structure);Bridge Research (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Sciences);and Patient-Oriented Research (Clinical Research and Survivorship, Outcomes and Risk). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the 10 research programs depends on services provided by 34 core facilities. We are requesting funding from the Cancer Center Support Grant (CCSG) for 21 of these core facilities. During the next five years, MSKCC will continue to enlarge its clinical and research facilities and its research and training programs in key research areas. Support is requested to provide developmental funding for the laboratories of new investigators recruited in research areas aligned with the Center's strategic vision, to support cross-disciplinary pilot projects in population science research, and to support the core facilities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA008748-48
Application #
8607691
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1997-01-20
Project End
2018-12-31
Budget Start
2014-03-13
Budget End
2014-12-31
Support Year
48
Fiscal Year
2014
Total Cost
$5,199,621
Indirect Cost
$2,273,554
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Berry, Sean L; Tierney, Kevin P; Elguindi, Sharif et al. (2018) Five years' experience with a customized electronic checklist for radiation therapy planning quality assurance in a multicampus institution. Pract Radiat Oncol 8:279-286
Breitbart, William (2018) Jimmie C. Holland, M.D. Psychosomatics 59:123-124
Geller, Shamir; Pitter, Ken; Moskowitz, Alison et al. (2018) Treatment of Vulvar Mycosis Fungoides Tumors With Localized Radiotherapy. Clin Lymphoma Myeloma Leuk 18:e279-e281
Romesser, Paul B; Pei, Xin; Shi, Weiji et al. (2018) Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients. Int J Radiat Oncol Biol Phys 100:59-67
Ankerst, Donna P; Straubinger, Johanna; Selig, Katharina et al. (2018) A Contemporary Prostate Biopsy Risk Calculator Based on Multiple Heterogeneous Cohorts. Eur Urol 74:197-203
Scott, Jessica M; Nilsen, Tormod S; Gupta, Dipti et al. (2018) Exercise Therapy and Cardiovascular Toxicity in Cancer. Circulation 137:1176-1191
Routy, Bertrand; Le Chatelier, Emmanuelle; Derosa, Lisa et al. (2018) Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359:91-97
Hou, Xiaowei; Burstein, Shana R; Long, Stephen Barstow (2018) Structures reveal opening of the store-operated calcium channel Orai. Elife 7:
Mori, Shoko; Navarrete-Dechent, Cristian; Petukhova, Tatyana A et al. (2018) Tumor Board Conferences for Multidisciplinary Skin Cancer Management: A Survey of US Cancer Centers. J Natl Compr Canc Netw 16:1209-1215
Pronier, Elodie; Cifani, Paolo; Merlinsky, Tiffany R et al. (2018) Targeting the CALR interactome in myeloproliferative neoplasms. JCI Insight 3:

Showing the most recent 10 out of 8799 publications